Hostname: page-component-cd9895bd7-gbm5v Total loading time: 0 Render date: 2024-12-27T11:28:11.921Z Has data issue: false hasContentIssue false
  • English
  • Français

A guide to new anticoagulant medications for ENT surgeons

Published online by Cambridge University Press:  11 December 2015

M Bajalan ,
T C Biggs ,
S Jayaram ,
J Mainwaring  and
R Salib
M Bajalan*
Affiliation:
Department of ENT Surgery, University Hospital Southampton NHS Foundation Trust, Southampton, UK
T C Biggs
Affiliation:
Department of ENT Surgery, University Hospital Southampton NHS Foundation Trust, Southampton, UK
S Jayaram
Affiliation:
Department of ENT Surgery, Birmingham City Hospital, Southampton, UK
J Mainwaring
Affiliation:
Department of Haematology, Royal Bournemouth & Poole Hospitals, Southampton, UK
R Salib
Affiliation:
Department of ENT Surgery, University Hospital Southampton NHS Foundation Trust, Southampton, UK
*
Address for correspondence: Dr M Bajalan, 33 Fordbridge Road, Ashford, Middlesex TW15 2TB, UK E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives:

This study aimed to ascertain otolaryngologists’ current knowledge of new (e.g. apixaban, rivaroxaban) and old (e.g. warfarin) anticoagulant medications, and to provide an educational overview of new anticoagulants for use by surgeons.

Methods:

A questionnaire survey was distributed across the Wessex region, UK, to ascertain the levels of knowledge of and confidence in managing patients taking various anticoagulants. In total, 50 questionnaires were completed (41 by trainees and 9 by consultants). A literature review of new anticoagulant medications was then conducted.

Results:

In general, there was poor clinical and pharmacokinetic knowledge of newly licensed anticoagulant medications. Respondents were more confident in the use of older vs newer forms of anticoagulants. This was true across all grades of doctors, but particularly at the senior level. All respondents stated that they would like to see an educational resource on anticoagulants.

Conclusion:

Knowledge of newly licensed anticoagulation medications is poor. This study has produced an educational resource for the management of anticoagulant agents. A thorough knowledge of these drugs is essential for the acute management of bleeding patients and in peri-operative surgical planning.

Keywords

PyrazolesAnticoagulantsOtolaryngologyPatient Care Management
Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 129 , Issue 12 , December 2015 , pp. 1167 - 1173
Copyright
Copyright © JLO (1984) Limited 2015 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Presented as an oral presentation at the South West ENT Academic Meeting, 6 June 2014, Bath, UK

References

1National Institute for Health and Care Excellence. The management of atrial fibrillation. In: http://guidance.nice.org.uk/CG36 [1 June 2014]Google Scholar
2Sardella, G, Mancone, M, Biondi-Zoccai, G, Conti, G, Canali, E, Stio, R et al. Beneficial impact of prolonged dual antiplatelet therapy after drug-eluting stent implantation. J Interv Cardiol 2012;25:596–603CrossRefGoogle ScholarPubMed
3Smith, J, Siddiq, S, Dyer, C, Rainsbury, J, Kim, D. Epistaxis in patients taking oral anticoagulant and antiplatelet medication: prospective cohort study. J Laryngol Otol 2011;125:38–42CrossRefGoogle ScholarPubMed
4Vedovati, MC, Becattini, C, Agnelli, G. Combined oral anticoagulants and antiplatelets: benefits and risks. Intern Emerg Med 2010;5:281–90CrossRefGoogle ScholarPubMed
5Hollowell, J, Ruigómez, A, Johansson, S, Wallander, MA, García-Rodríguez, LA. The incidence of bleeding complications associated with warfarin treatment in general practice in the United Kingdom. Br J Gen Pract 2003;53:312–14Google ScholarPubMed
6De Caterina, R, Husted, S, Wallentin, L, Andreotti, F, Arnesen, H, Bachmann, F et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes. ESC working group on thrombosis – task force on anticoagulants in heart disease position paper. J Am Coll Cardiol 2012;59:1413–25CrossRefGoogle Scholar
7Sorbera, LA, Bozzo, J, Castaner, J. Dabigatran/dabigatran etexilate. Drugs Fut 2005;30:877–85CrossRefGoogle Scholar
8Stangier, J, Eriksson, BI, Dahl, OE, Ahnfelt, L, Nehmiz, G, Stähler, H et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005;45:555–63CrossRefGoogle ScholarPubMed
9Eerenberg, ES, Kamphuisen, PW, Sijpkens, MK, Meijers, JC, Buller, HR, Levi, M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011;124:1573–9CrossRefGoogle ScholarPubMed
10Jiang, J, Hu, Y, Zhang, J, Yang, J, Mueck, W, Kubitza, D et al. Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban – an oral, direct factor Xa inhibitor – in elderly Chinese subjects. Thromb Haemost 2010;103:234–41CrossRefGoogle ScholarPubMed
11NICE clinical knowledge summaries. In: http://cks.nice.org.uk/anticoagulation-oral#!scenariorecommendation:29 [23 May 2014]Google Scholar
12Massicotte, A. A practice tool for the new oral anticoagulants. Can Pharm J (Ott) 2014;147:25–32CrossRefGoogle ScholarPubMed